StockData

Korro Bio vs Neurogene

KRRO and NGNE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRRO and NGNE compare

Neurogene is the larger company, worth 2.5 times as much as Korro Bio ($462M against $181M).

Neurogene scores higher on the StockData Score (7 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRRONGNE
Size and price
Market cap$181M$462M
Share price$12.32$23.10
Change, 1 year103%1.4%
Change, 5 years−95.6%−77.4%
Beta (5Y)2.472.01
Employees58131
StockData Score
Total score57 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S76.2×–
P/B–2.1×
FCF yield−37.6%−19.0% (better)
Growth
Revenue growth (TTM)−62.1%–
Revenue growth, 5Y average−29.6%–
Profitability
Operating margin−4625%–
Net margin−4477%–
FCF margin−2866%–
Return on equity–−45.3%
Financial health
Debt / equity–0.00
Interest coverage–−60673.0×
Current ratio9.5510.64 (better)
Altman Z-score−3.237.17 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%86.5%
Held by insiders27.4%15.9%
Insider net buying, 12 months$15.0M (better)−$1.1M
Short interest, % of float16.4%33.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.